scholarly journals Cost-effectiveness Analysis of Schatzker V Tibial Plateau Fractures Treated with Locking Plate in a University Hospital

2021 ◽  
Vol 10 (09) ◽  
pp. 12-16
Author(s):  
José Eduardo Nogueira Forni ◽  
Stefan Corniani Aran ◽  
João Pedro Passos Godinho ◽  
Wahi Jalikji
Keyword(s):  
Cost Effectiveness ◽  
Tibial Plateau ◽  
Locking Plate ◽  
Cost Effectiveness Analysis ◽  
Tibial Plateau Fractures ◽  
University Hospital ◽  
Effectiveness Analysis

scholarly journals BRCA mutation carrier detection. A model-based cost-effectiveness analysis comparing the traditional family history approach and the testing of all patients with breast cancer

ESMO Open ◽  
2018 ◽  
Vol 3 (3) ◽  
pp. e000328 ◽  
Author(s):  
Jan Norum ◽  
Eli Marie Grindedal ◽  
Cecilie Heramb ◽  
Inga Karsrud ◽  
Sarah Louise Ariansen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cost Effectiveness ◽  
Family History ◽  
Brca Mutation ◽  
Unit Cost ◽  
Cost Effectiveness Analysis ◽  
University Hospital ◽  
Healthcare Perspective ◽  
Model Based ◽  
Effectiveness Analysis

BackgroundIdentification of BRCA mutation carriers among patients with breast cancer (BC) involves costs and gains. Testing has been performed according to international guidelines, focusing on family history (FH) of breast and/or ovarian cancer. An alternative is testing all patients with BC employing sequencing of the BRCA genes and Multiplex Ligation Probe Amplification (MLPA).Patients and methodsA model-based cost-effectiveness analysis, employing data from Oslo University Hospital, Ullevål (OUH-U) and a decision tree, was done. The societal and the healthcare perspectives were focused and a lifetime perspective employed. The comparators were the traditional FH approach used as standard of care at OUH-U in 2013 and the intervention (testing all patients with BC) performed in 2014 and 2015 at the same hospital. During the latter period, 535 patients with BC were offered BRCA testing with sequencing and MLPA. National 2014 data on mortality rates and costs were implemented, a 3% discount rate used and the costing year was 2015. The incremental cost-effectiveness ratio was calculated in euros (€) per life-year gained (LYG).ResultsThe net healthcare cost (healthcare perspective) was €40 503/LYG. Including all resource use (societal perspective), the cost was €5669/LYG. The univariate sensitivity analysis documented the unit cost of the BRCA test and the number of LYGs the prominent parameters affecting the result.Diagnostic BRCA testing of all patients with BC was superior to the FH approach and cost-effective within the frequently used thresholds (healthcare perspective) in Norway (€60 000–€80 000/LYG).

scholarly journals Cost-effectiveness of Herceptin®: A standard cost model for breast-cancer treatment in a Belgian university hospital

2005 ◽  
Vol 21 (1) ◽  
pp. 132-137 ◽  
Author(s):  
Mattias J. Neyt ◽  
Johan A. Albrecht ◽  
Bart Clarysse ◽  
Véronique F. Cocquyt
Keyword(s):  
Breast Cancer ◽  
Cost Effectiveness ◽  
Cost Model ◽  
Treatment Options ◽  
Cost Effectiveness Analysis ◽  
University Hospital ◽  
Future Research ◽  
Literature Study ◽  
Her2 Receptor ◽  
Effectiveness Analysis

Objectives: The objective of this study was to conduct a cost-effectiveness analysis of Herceptin® from the hospital's point of view. This new biotechnological pharmaceutical is a humanized monoclonal antibody that targets the HER2 receptor, an important anti-cancer target.Methods: A cost model with standard diagnostic and treatment options for breast cancer was set up for a Belgian university hospital in close collaboration with its specialists. Direct and indirect costs were calculated for each diagnostic and treatment option using the micro-costing method. Effectiveness was estimated through a literature study. The model allowed us to take cost consequences in other stages of the model into account and to calculate changes in monthly treatment costs from different “starting points.” With an incremental cost-effectiveness analysis, differences in costs and effectiveness with and without Herceptin® were compared.Results: Over the complete treatment period from diagnosis until the metastatic phase, monthly costs for the hospital rose from €85.07 to €90.35 for stage I diagnosed breast cancer when adding Herceptin® to the model. In the metastatic phase alone, these costs rose from €1,132.33 to €1,256.23. With Herceptin®, we found an extra cost of €3,981.44 per extra life-month.Conclusions: This cost-effectiveness ratio was rather high, because Herceptin® was quite expensive and the product was additive in its current use and did not replace existing treatments. Future research will concentrate on alternative applications of Herceptin® based on ongoing Herceptin® trials and expert opinions.

scholarly journals Cost-effectiveness analysis is a mandatory strategy for health systems: evidence from a study involving therapies for hepatitis C

2020 ◽  
Vol 36 (2) ◽  
Author(s):  
João Paulo Vilela Rodrigues ◽  
Maurílio de Souza Cazarim ◽  
Silvana Gama Florencio Chachá ◽  
Ana de Lourdes Candolo Martinelli ◽  
Leonardo Régis Leira Pereira
Keyword(s):  
Cost Effectiveness ◽  
Hepatitis C ◽  
Real Life ◽  
Dual Therapy ◽  
Cost Effectiveness Analysis ◽  
University Hospital ◽  
Virus Genotype ◽  
Health Technologies ◽  
Effectiveness Analysis ◽  
The Impact

Abstract: Cost-effectiveness analysis is essential in health decision making. Several countries use it as synthesis of evidence to incorporate health technologies. The protease inhibitors (PI) boceprevir (BOC) and telaprevir (TVR) are indicated for chronic hepatitis C treatment and were incorporated in guidelines worldwide. Pre-marketing clinical trials showed higher sustained virological response rates in relation to previous therapies, but the incorporation of PIs generated a significant financial impact. The aim of this study was to discuss the relevance of cost-effectiveness analysis through a study that involved the inclusion of PIs in a clinical protocol. The analysis was part of a real-life study that included patients infected with hepatitis C virus genotype 1 treated in a tertiary university hospital in Brazil. Triple therapies (TT) with ribavirin (RBV), peginterferon α-2a (Peg-INF α-2a) and BOC or TVR were compared to dual therapy with RBV and Peg-INF α-2a. Sensitivity analysis of the cost-effectiveness ratio indicated an 88.2% chance of TTs presenting a higher cost per cure. The incremental cost-effectiveness ratios (ICER) exceeded the Brazilian gross domestic product (GDP) per capita by three times in all proposed scenarios. The sensitivity of ICER showed an 88.4% chance of TT not being cost-effective. The impact of PI incorporation was negative and the conduct about this could have been different if a previous cost-effectiveness analysis had been conducted.

Cost-Effectiveness Analysis Methods

2002 ◽  
Author(s):  
Eugene Laska ◽  
Morris Meisner ◽  
Carole Siegel ◽  
Joseph Wanderling
Keyword(s):  
Cost Effectiveness ◽  
Cost Effectiveness Analysis ◽  
Effectiveness Analysis ◽  
Analysis Methods
Sign in / Sign up

Export Citation Format

Share Document